ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 460

Fertility of Women with Rheumatoid Arthritis: Disease Activity Negatively Correlates with Serum AMH Levels

Camille Valdeyron1, Martin SOUBRIER 2, Bruno Pereira 1, Arnaud Constantin 3, Jacques Morel 4, Philippe Gaudin 5, Bernard Combe 6 and Florence Brugnon 1, 1CHU CLERMONT-FERRAND, Clermont-Ferrand, France, 2CHU Gabriel Montpied, Clermont Ferrand, Auvergne, France, 3CHU TOUOUSE, TOULOUSE, France, 4CHU MONTPELLIER, MONTPELLIER, France, 5Rheumatology Department, CHU Grenoble Alpes Hôpital Sud and GREPI - Université Grenoble Alpes, EA7408, Grenoble - Echirolles, France, 6CHU Montpellier, Montpellier University, Montpellier, France

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Early Rheumatoid Arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with rheumatoid arthritis (RA) display a higher infertility prevalence compared with the general population. Disease-related inflammation and RA treatments are likely to be the main factors explaining the RA patients’ infertility. Nevertheless, the tangible link between these different factors and the decline in  women’s fertility has never been clearly demonstrated. This study sought to examine the impact of RA disease activity and treatments on ovarian reserve measured by serum AMH levels in a large patient cohort over 36 months. Using this analysis, we sought to better define the indications for fertility preservation in RA patients.

Methods: Patient and serum analysis data were derived from the French national prospective cohort ESPOIR (Etude et Suivi des POlyarthrites Indifférenciées Récentes). Enrolled patients (n= 117; 18-37-year-olds) fulfilling ACR/EULAR2010 criteria for RA were not receiving any medication at enrolment time (T0). Patients were examined and serum AMHs level measured at T0, 6(T6), 12(T12), 24(T24), and 36(T36) months post-diagnosis.

Serum AMH measurements were performed using the electrochemiluminescence method (analyser Cobas® e411). The impact of both RA activity (evaluated by DAS28 scores and CRP levels) and treatments (methotrexate and corticosteroids) was evaluated at each study visit.

Results: Overall, 117 women from the ESPOIR cohort, aged 18-37 years, were included. The mean age was 29.2+/-5.3 years, mean body mass index 22.96 (+/-3.57)Kg/m2, mean DAS 28 4.95 (+/-1.24) (range: 1.57-8.30), thus reflecting moderate RA activity, and mean CRP 22.5+/-34mg/L.

A gradual decrease in patients’ serum AMH levels was observed over time, in line with the descending curve described in the literature for healthy women (Kelsey et al.,2011). Serum AMH levels of RA patients in comparison with the values considered normal for age did not reveal any significant differences at T6, T12, T24, and T36 (p >0.05). We did not observe any impact of RA treatments on serum AMH levels, irrespective of the medication administered, and even after adjusting for age and DAS 28 score (p=0.81). We demonstrated an inverse correlation between serum AMH level variations and inflammation parameters (DAS28: r=-0.27, p=0.003; CRP: r=-0.16, p=0.06).

Conclusion: This is the first study to determine serum AMH levels of a large cohort of young RA patients over 36 months. A quick disease activity limitation appears required to limit ovarian reserve alterations. Oocytes or ovarian tissues are not likely to be necessary if inflammation is promptly controlled. No impact of RA treatments was observed. More studies are required to further explain the pathophysiological mechanisms underlying these associations.


Disclosure: C. Valdeyron, None; M. SOUBRIER, None; B. Pereira, None; A. Constantin, Novartis, 8, Pfizer, 5, Sanofi, 5, SANOFI, 8, UCB, 5, 8; J. Morel, None; P. Gaudin, None; B. Combe, AbbVie, 5, BMS, 5, 8, Chugai, 5, 8, Eli Lilly, 5, Eli Lilly and Company, 5, 8, Gilead, 5, 8, Gilead Sciences, Inc., 5, 8, Janssen, 5, Lilly, 5, 8, MSD, 2, 5, 8, Novartis, 5, Pfizer, 2, 5, 8, Roche, 2, 5, 8, Roche-Chugai, 5, 8, Sanofi, 5, UCB, 5, USD, 5; F. Brugnon, None.

To cite this abstract in AMA style:

Valdeyron C, SOUBRIER M, Pereira B, Constantin A, Morel J, Gaudin P, Combe B, Brugnon F. Fertility of Women with Rheumatoid Arthritis: Disease Activity Negatively Correlates with Serum AMH Levels [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/fertility-of-women-with-rheumatoid-arthritis-disease-activity-negatively-correlates-with-serum-amh-levels/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fertility-of-women-with-rheumatoid-arthritis-disease-activity-negatively-correlates-with-serum-amh-levels/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology